RxDoctor Payments Data

Sarah Keith

Family · Bentonville, ARNPI 1992113294

Payments from drug & device makers

$6,380in general payments, 2019–2025

Across 370 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$990
  • Pfizer$673
  • GSK$627
  • AstraZeneca$600
  • Novo Nordisk$584
  • Lilly USA, LLC$472
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$6,380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,380 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$22,834
Medicare patients
114
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide32$35,830
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$28,258
FarxigaDapagliflozin Propanediol16$14,453
JardianceEmpagliflozin11$11,263
Albuterol Sulfate HfaAlbuterol Sulfate51$868
Ventolin HfaAlbuterol Sulfate12$632
Levothyroxine Sodium74$602
Atorvastatin Calcium56$501
Rosuvastatin Calcium18$498
Pantoprazole Sodium47$444
Gabapentin18$405
Omeprazole25$369
Amlodipine Besylate51$362
Sertraline Hcl20$276
Doxycycline Hyclate33$259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$472$35,83032 claims
GSKTrelegy Ellipta$627$28,25840 claims
AstraZenecaFarxiga$600$14,45316 claims
Boehringer IngelheimJardiance$190$11,26311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Bentonville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →